Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/cap.2013.0075 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Review of Sex and Gender Factors in Stimulant Treatment for ADHD: Knowledge Gaps and Future Directions.
J Atten Disord
January 2025
University of Amsterdam, The Netherlands.
Objective: Stimulant medications are the primary pharmacological intervention for ADHD, yet our understanding of how sex and gender impact stimulant treatment outcomes remains limited. Clinical guidelines do not differ for female and male individuals despite possible sex and gender-related differences in effectiveness, adverse events, and pharmacokinetics. This theoretical framework identifies five key knowledge gaps relating to sex and gender effects in stimulant treatment.
View Article and Find Full Text PDFEffects of methylphenidate on sensitivity to reinforcement delay, magnitude, and probability: Implications for impulsive and risky choice.
J Exp Anal Behav
January 2025
Department of Psychology, University of North Carolina Wilmington, Wilmington, NC, USA.
Under rapid-acquisition, concurrent-chains choice procedures, psychomotor stimulants typically decrease the sensitivity of responding to changes in separate dimensions of reinforcement. Across two experiments, pigeons chose between outcomes that differed in terms of reinforcement delay and magnitude (the dimensions involved in delay discounting or "impulsive" choice; Experiment 1) or reinforcement probability and magnitude (the dimensions involved in probability discounting or "risky" choice; Experiment 2). Outcomes associated with each terminal link were varied independently and pseudorandomly across sessions such that in dominated sessions one terminal link was favorable in terms of both dimensions (sooner, larger in Experiment 1 and more likely, larger in Experiment 2) and in trade-off sessions each terminal link was favorable in terms of a different dimension.
View Article and Find Full Text PDFPharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin-3, and Catechol-O-Methyltransferase.
Am J Med Genet B Neuropsychiatr Genet
January 2025
Biruni University Research Center (B@MER), Biruni University, Istanbul, Turkey.
Pharmacogenetic studies involving Carboxylesterase 1 (CES1), Latrophilin-3 (LPHN3), and Catechol-O-methyltransferase (COMT) revealed individual differences regarding therapeutic response in children with attention deficit hyperactivity disorder (ADHD) under methylphenidate (MPH) treatment. This study aimed to evaluate MPH's association with the adverse effect status in children and its relationship with CES1, LPHN3, and COMT in the Turkish population. The study included 102 children and adolescents with ADHD, who were categorized as responders, or the adverse effect group based on their treatment response.
View Article and Find Full Text PDFD1 dopamine receptor antagonists as a new therapeutic strategy to treat autistic-like behaviours in lysosomal storage disorders.
Mol Psychiatry
January 2025
Telethon Institute of Genetics and Medicine, Via Campi Flegrei 34, Pozzuoli, 80078, Naples, Italy.
Lysosomal storage disorders characterized by defective heparan sulfate (HS) degradation, such as Mucopolysaccharidosis type IIIA-D (MPS-IIIA-D), result in neurodegeneration and dementia in children. However, dementia is preceded by severe autistic-like behaviours (ALBs), presenting as hyperactivity, stereotypies, social interaction deficits, and sleep disturbances. The absence of experimental studies on ALBs' mechanisms in MPS-III has led clinicians to adopt symptomatic treatments, such as antipsychotics, which are used for non-genetic neuropsychiatric disorders.
View Article and Find Full Text PDFPathogenesis-directed therapy of methylphenidate-induced oxidative heart damage in rats.
Front Pharmacol
January 2025
Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Türkiye.
Aim: The current study aimed to investigate the protective effects of adenosine triphosphate (ATP), metyrosine, and melatonin on possible methylphenidate cardiotoxicity in rats using biochemical and histopathological methods.
Methods: Thirty rats were separated into five groups: healthy (HG), methylphenidate (MP), ATP + methylphenidate (ATMP), metyrosine + methylphenidate (MSMP), and melatonin + methylphenidate (MLMP). ATP (5 mg/kg) was given intraperitoneally once daily, metyrosine (50 mg/kg) orally twice daily, and melatonin (10 mg/kg) orally once daily.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!